Activities of respiratory chain complexes and citrate synthase influenced by pharmacologically different antidepressants and mood stabilizers

Neuroendocrinology Letters

Volumn 31, Issue 3, 2010, Pages 336-342

  Hroudova, Jana ^a   Fisar, Zdenek ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Antidepressive agents; Citric acid cycle; Electron transport chain; Mood stabilizers

Indexed keywords

AMITRIPTYLINE; CITALOPRAM; CITRATE SYNTHASE; DESIPRAMINE; IMIPRAMINE; LITHIUM; MIRTAZAPINE; MOCLOBEMIDE; MULTIENZYME COMPLEX; OLANZAPINE; TIANEPTINE; VALPROIC ACID; VENLAFAXINE; ANTIDEPRESSANT AGENT; BENZODIAZEPINE DERIVATIVE; CYTOCHROME C OXIDASE; LITHIUM DERIVATIVE; NEUROLEPTIC AGENT; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); UBIQUINOL CYTOCHROME C REDUCTASE;

ANIMAL TISSUE; ARTICLE; ENZYME ACTIVITY; EXPERIMENTAL PIG; MOOD DISORDER; NONHUMAN; RESPIRATORY CHAIN; ANIMAL; BRAIN CORTEX; COMPARATIVE STUDY; DRUG EFFECTS; ELECTRON TRANSPORT; IN VITRO STUDY; METABOLISM; MITOCHONDRION; SWINE;

ANIMALS; ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; CEREBRAL CORTEX; CITRATE (SI)-SYNTHASE; ELECTRON TRANSPORT; ELECTRON TRANSPORT COMPLEX I; ELECTRON TRANSPORT COMPLEX III; ELECTRON TRANSPORT COMPLEX IV; IN VITRO TECHNIQUES; LITHIUM COMPOUNDS; MITOCHONDRIA; SWINE; VALPROIC ACID;

EID: 77955444419     PISSN: 0172780X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Ben-Shachar D, Karry R (2008). Neuroanatomical pattern of mitochondrial complex I pathology varies between schizophrenia, bipolar disorder and major depression. PLoS ONE. 3(11): e3676.
2. Corrêa C, Amboni G, Assis LC, Martins MR, Kapczinski F, Streck EL, et al (2007). Effects of lithium and valproate on hippocampus citrate synthase activity in an animal model of mania. Prog Neuropsychopharmacol Biol Psychiatry. 31(4): 887-891. (Pubitemid 46660301)
3. Duman RS, Heninger GR, Nestler, EJ (1997). A molecular and cellular theory of depression. Arch Gen Psychiatry. 54: 597-606.
4. Duman RS (2002) Synaptic plasticity and mood disorders. Mol Psychiatry. 7: S29-S34.
5. Dykens JA, Jamieson JD, Marroquin LD, Nadanaciva S, Xu JJ, Dunn MC, et al (2008). In vitro assessment of mitochondrial dysfunction and cytotoxicity of nefazodone, trazodone, and buspirone. Toxicol Sci. 103(2): 335-345.
6. Einat, H, Manji HK (2006). Cellular plasticity cascades: genes-to-behavior pathways in animal models of bipolar disorder. Biol Psychiatry. 59(12): 1160-1171.
7. Fišar Z, Raboch J (2008). Depression, antidepressants, and peripheral blood components. Neuroendocrinol Lett. 29(1): 17-28.
8. Fišar Z, Hroudová J (2010). Intracellular signalling pathways and mood disorders. Folia Biol. 56, in press.
9. Fišar Z, Hroudová J, Raboch J (2010). Inhibition of monoamine oxidase activity by antidepressants and mood stabilizers. Neuroendocrinol Lett. 31, in press.
10. Folbergrová J, Ješina P, Drahota Z, Lisý V, Haugvicová R, Vojtíšková A, et al (2007). Mitochondrial complex I inhibition in cerebral cortex of immature rats following homocysteic acid-induced seizures. Exp Neurol. 204(2): 597-609.
11. Gould TD, Manji HK (2005). Glycogen synthase kinase-3: a putative molecular target for lithium mimetic drugs. Neuropsychopharmacology. 30(7): 1223-1237.
12. Hwang J, Zheng LT, Ock J, Lee MG, Kim SH, Lee HW, et al (2008). Inhibition of glial inflammatory activation and neurotoxicity by tricyclic antidepressants. Neuropharmacology. 55(5): 826-834.
13. Jou S-H, Chiu N-Y, Liu C-S (2009). Mitochondrial dysfunction and psychiatric disorders. Chang Gung Med J. 32(4): 370-379.
14. Kato T, Kato N (2000). Mitochondrial dysfunction in bipolar disorder. Bipolar Disord. 2(3 Pt 1): 180-190.
15. Kato T, Kunugi H, Nanko S, Kato N (2001). Mitochondrial DNA polymorphisms in bipolar disorder. J Affect Disord. 62(3):151-164. (Pubitemid 32167082)
16. 2+ signalling in transformed lymphoblastoid cells from patients with bipolar disorder. Int J Neuropsychopharmacol. 6(4): 379-389.
17. Kato T (2007). Mitochondrial dysfunction as the molecular basis of bipolar disorder: therapeutic implications. CNS Drugs. 21(1): 1-11.
18. Kato T, Kakiuchi C, Iwamoto K (2007). Comprehensive gene expression analysis in bipolar disorder. Can J Psychiatry. 52(12): 763-771.
19. Kato T (2008). Role of mitochondrial DNA in calcium signaling abnormality in bipolar disorder. Cell Calcium. 44(1): 92-102.
20. Kirby DM, Thorburn DR, Turnbull DM, Taylor RW (2007). Biochemical assays of respiratory chain complex activity. In: Pon LA. Schon EA, editors. Mitochondria, 2nd Edition (Methods in Cell Biology, Vol. 80). San Diego: Elsevier. p. 93-119.
21. Lambert PD, McGirr KM, Ely TD, Kilts CD, Kuhar MJ (1999). Chronic lithium treatment decreases neuronal activity in the nucleus accumbens and cingulate cortex of the rat. Neuropsychopharmacology. 21(2): 229-237.
22. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ (1951). Protein measurement with the Folin phenol reagent. J Biol Chem. 193: 265-275.
23. Mattson MP, Gleichmann M, Cheng A (2008). Mitochondria in neuroplasticity and neurological disorders. Neuron. 60(5): 748-766.
24. Maurer I, Möller HJ (1997). Inhibition of complex I by neuroleptics in normal human brain cortex parallels the extrapyramidal toxicity of neuroleptics. Mol Cell Biochem. 174(1-2): 255-259. (Pubitemid 27404200)
25. Maurer IC, Schippel P, Volz H-P (2009). Lithium-induced enhancement of mitochondrial oxidative phosphorylation in human brain tissue. Bipolar Disord. 11(5): 515-522.
26. Neustadt J, Pieczenik SR (2008). Medication-induced mitochondrial damage and disease. Mol Nutr Food Res. 52(7): 780-788.
27. Orth M, Schapira AH (2001). Mitochondria and degenerative disorders. Am J Med Genet. 106(1): 27-36.
28. Pathak RU, Davey GP (2008). Complex I and energy thresholds in the brain. Biochim Biophys Acta. 1777(7-8): 777-782.
29. Pittenger C, Duman RS (2008). Stress, depression, and neuroplasticity: a convergence of mechanisms. Neuropsychopharmacology. 33(1): 88-109.
30. Quiroz JA, Gray NA, Kato T, Manji HK (2008). Mitochondrially mediated plasticity in the pathophysiology and treatment of bipolar disorder. Neuropsychopharmacology. 33(11): 2551-2565.
31. Ragan CI, Wilson MT, Darley-Usmar VM, Lowe PN (1987). Subfractionation of mitochondria and isolation of the proteins of oxidative phosphorylation. In: Darley-Usmar VM, Rickwood D, Wilson MT, editors. Mitochondria. A Practical Approach. London: IRL Press, p. 79-112.
32. Rezin GT, Amboni G, Zugno AI, Quevedo J, Streck EL (2009). Mitochondrial dysfunction and psychiatric disorders. Neurochem Res. 34(6): 1021-1029.
33. Rustin P, Chretien D, Bourgeron T, Gérard B, Rötig A, Saudubray JM, et al (1994). Biochemical and molecular investigations in respiratory chain deficiencies. Clin Chim Acta. 228(1): 35-51.
34. Scatena R, Bottoni P, Botta G, Martorana GE, Giardina B (2007). The role of mitochondria in pharmacotoxicology: a reevaluation of an old, newly emerging topic. Am J Physiol Cell Physiol. 293(1): C12-C21.
35. Shao L, Martin MV, Watson SJ, Schatzberg A, Akil H, Myers RM, et al (2008). Mitochondrial involvement in psychiatric disorders. Ann Med. 40(4): 281-295.
36. Srere PA (1969). Citrate synthase : [EC 4.1.3.7. Citrate oxaloacetate-lyase (CoA-acetylating)]. Methods Enzymol. 13: 3-11.
37. Stork C, Renshaw PF (2005). Mitochondrial dysfunction in bipolar disorder: evidence from magnetic resonance spectroscopy research. Mol Psychiatry. 10(10): 900-919. (Pubitemid 41486483)
38. Sun X, Wang J-F, Tseng M, Young LT (2006). Downregulation in components of the mitochondrial electron transport chain in the postmortem frontal cortex of subjects with bipolar disorder. J Psychiatry Neurosci. 31(3): 189-196.
39. Telford JE, Kilbride SM, Davey GP (2009). Complex I is rate-limiting for oxygen consumption in the nerve terminal. J Biol Chem. 284(14): 9109-9114.
40. Trounce IA, Kim YL, Jun AS, Wallace DC (1996). Assessment of mitochondrial oxidative phosphorylation in patient muscle biopsies, lymphoblasts, and transmitochondrial cell lines. Methods Enzymol. 264: 484-509. (Pubitemid 126516569)
41. Wang J-F (2007). Defects of mitochondrial electron transport chain in bipolar disorder: implications for mood-stabilizing treatment. Can J Psychiatry. 52(12): 753-762.
42. Wong-Riley MT (1989). Cytochrome oxidase: an endogenous metabolic marker for neuronal activity. Trends Neurosci. 12(3): 94-101.
43. Zarate CAJr, Singh J, Manji HK (2006). Cellular plasticity cascades: targets for the development of novel therapeutics for bipolar disorder. Biol Psychiatry. 59(11): 1006-1020.